Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

August 2019 | 48 pages | ID: E08C69DE7DAEN
GlobalData

Abstracts

Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Egalet Corp (Egalet), formerly Zyla Life Sciences, is a commercial-stage pharmaceutical company that commercializes innovative treatment options for inflammation and various types of pain. The company offers branded non-narcotic, nonsteroidal, and anti-inflammatory drugs and formulations including ketorolac tromethamine nasal spray, diclofenac, indomethacin, oxycodone HCI, USP, and meloxicam. Its acute and chronic pain products enable healthcare providers to address the issue of prescription abuse. The company harnesses its proprietary Guardian technology, a polymer matrix tablet technology, for advancing its pipeline products. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp Key Recent Developments

Jun 19,2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors
Jun 12,2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer
May 16,2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences
Nov 19,2018: Egalet announces third quarter 2018 financial results
Aug 08,2018: Egalet reports second quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Egalet Corp - Key Facts
Egalet Corp - Key Employees
Egalet Corp - Key Employee Biographies
Egalet Corp - Major Products and Services
Egalet Corp - History
Egalet Corp - Company Statement
Egalet Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Egalet Corp - Business Description
Product Category: Arymo ER
Performance
Product Category: Oxaydo
Performance
Product Category: Sprix Nasal Spray
Performance
R&D Overview
Egalet Corp - Corporate Strategy
Egalet Corp - SWOT Analysis
SWOT Analysis - Overview
Egalet Corp - Strengths
Egalet Corp - Weaknesses
Egalet Corp - Opportunities
Egalet Corp - Threats
Egalet Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Egalet Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 19, 2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors
Jun 12, 2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer
May 16, 2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences
Nov 19, 2018: Egalet announces third quarter 2018 financial results
Aug 08, 2018: Egalet reports second quarter 2018 financial results
Jun 07, 2018: Egalet Names John Varian Board Director
May 08, 2018: Egalet Reports First Quarter 2018 Financial Results
Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Egalet Corp, Key Facts
Egalet Corp, Key Employees
Egalet Corp, Key Employee Biographies
Egalet Corp, Major Products and Services
Egalet Corp, History
Egalet Corp, Other Locations
Egalet Corp, Subsidiaries
Egalet Corp, Key Competitors
Egalet Corp, Ratios based on current share price
Egalet Corp, Annual Ratios
Egalet Corp, Annual Ratios (Cont...1)
Egalet Corp, Interim Ratios
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Egalet Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Egalet Corp, Performance Chart (2014 - 2018)
Egalet Corp, Ratio Charts
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Teva Pharmaceutical Industries, Ltd. - Portfolio of Generic Products – US
Pfizer Consumer Healthcare
Nektar Therapeutics
Mallinckrodt LLC
Endo Pharmaceuticals Inc
Actavis LLC